Category: Novartis
-
Federal court dismisses Entresto antitrust suit against Novartis: patent listing in Orange Book was proper
Judge Liman held that the U.S. Patent No. 8,101,659 claims the active ingredients on Entresto’s FDA label, so its Orange Book listing was proper, ending a payor’s antitrust case with prejudice.
-
EWHC hinders Accord’s plans to launch Entresto competing product in Novartis patent dispute
Mr. Justice Meade of the High Court of Justice for England & Wales has held that all of Accord’s “attacks” on a Novartis Entresto patent have failed, and its own intended competing product would infringe the defendant’s supplementary protection certificate.